VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 121 filers reported holding VERVE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,375,000 | -45.8% | 500,000 | -58.3% | 0.72% | -36.6% |
| Q1 2023 | $17,304,000 | -1.8% | 1,200,000 | +31.7% | 1.14% | +3.7% |
| Q4 2022 | $17,629,998 | -43.7% | 911,111 | 0.0% | 1.10% | -26.2% |
| Q3 2022 | $31,297,000 | +120.9% | 911,111 | -1.7% | 1.49% | +113.8% |
| Q2 2022 | $14,166,000 | -17.2% | 927,100 | +23.6% | 0.70% | -22.7% |
| Q1 2022 | $17,115,000 | -33.7% | 750,000 | +7.1% | 0.90% | -26.1% |
| Q4 2021 | $25,809,000 | -8.5% | 700,000 | +16.7% | 1.22% | -16.2% |
| Q3 2021 | $28,200,000 | -41.0% | 600,000 | -24.4% | 1.46% | -31.2% |
| Q2 2021 | $47,794,000 | – | 793,265 | – | 2.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $26,636,807 | 17.30% |
| Alphabet Inc. | 10,549,086 | $139,880,880 | 8.98% |
| Casdin Capital, LLC | 2,954,710 | $39,179,455 | 4.34% |
| MPM BioImpact LLC | 857,940 | $11,376,284 | 3.04% |
| Saltoro Capital, LP | 66,500 | $881,790 | 0.79% |
| ARK Investment Management | 5,200,567 | $68,959,525 | 0.53% |
| Redmile Group, LLC | 809,777 | $10,737,643 | 0.51% |
| Ikarian Capital, LLC | 2,413 | $3,199,638 | 0.38% |
| Logos Global Management LP | 215,000 | $2,850,900 | 0.38% |
| Nikko Asset Management Americas, Inc. | 2,147,243 | $28,429,497 | 0.34% |